ALPRESS L.P. 2.5 mg, osmotic tablet with extended release 30 tablets
Active ingredients: Prazosin hydrochloride, Prazosin
Commercialized according to BDPMDispensing in France: Prescription only
Osmotic tablet30 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- ALPRESS L.P. 2,5 mg, comprimé osmotique à libération prolongée
- Pharmaceutical form
- comprimé osmotique
- Route of administration
- orale
- Presentation description
- plaquette(s) PVC-Aluminium de 30 comprimé(s)
- Marketing authorisation holder
- PFIZER HOLDING FRANCE
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 1 Sept 2025
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
69537839CIP73311775CIP133400933117757Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| PRAZOSINE (CHLORHYDRATE DE)comprimé | 3,01 mg · un comprimé | SA |
| PRAZOSINE BASEcomprimé | 2,50 mg · un comprimé | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.